11 results
Search Results
2. Osteopontin but not parathyroid hormone-related protein predicts prognosis in human renal cell carcinoma.
- Author
-
PAPWORTH, KARIN, BERGH, ANDERS, GRANKVIST, KJELL, LJUNGBERG, BÖRJE, SANDLUND, JOHANNA, and RASMUSON, TORGNY
- Subjects
THERAPEUTIC use of cytokines ,ACADEMIC medical centers ,CHI-squared test ,CONFIDENCE intervals ,IMMUNOHISTOCHEMISTRY ,MULTIVARIATE analysis ,RADIONUCLIDE imaging ,REGRESSION analysis ,RENAL cell carcinoma ,RESEARCH funding ,STATISTICS ,U-statistics ,DATA analysis ,PROPORTIONAL hazards models ,DATA analysis software ,KAPLAN-Meier estimator ,PROGNOSIS - Abstract
Objective. To evaluate the relationship between osteopontin (OPN) in serum and plasma and parathyroid hormone-related protein (PTHrP) in serum, plasma and tumour tissue, and to assess the prognostic impact of OPN and PTHrP in human renal cell carcinoma (RCC). Material and methods. The study included 269 patients with RCC. In 189 patients, immuno-histochemical (IHC) PTHrP tumour tissue expression was evaluated, and OPN and PTHrP in serum were assessed. In 80 patients, plasma OPN and PTHrP were analysed. Tumour type, TNM stage, nuclear grade and RCC-specific survival were also registered. In a sub-group, IHC expression of CD 31 was assessed. The prognostic information of the factors was analysed using uni- and multivariate analyses. Results.The median OPN level was 2.3 times higher in plasma than in serum. Serum OPN was significantly higher in patients with papillary RCC compared to clear cell RCC and chromophobe RCC. Both serum and plasma OPN levels were positively correlated to TNM stage and nuclear grade. Multivariate analysis showed that serum and plasma OPN levels were independent prognostic factors for RCC-specific survival, along with TNM stage. Immunohistochemical expression of PTHrP associated to TNM stage but not to nuclear grade or serum OPN. Furthermore, IHC expression of PTHrP was positively correlated to serum PTHrP but inversely to tumour CD31 expression. Plasma PTHrP was increased in 20% of the patients and related to TNM stage but not to nuclear grade. Plasma OPN was significantly higher in patients with increased PTHrP levels, compared to those with normal levels. Conclusion. Plasma OPN levels differed between RCC types, and in clear cell RCC, both serum and plasma OPN levels were independent predictors of survival. We found no evidence for prognostic value related to circulating levels or the IHC expression of PTHrP. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
3. Anxiety and depression in oncology patients; a longitudinal study of a screening, assessment and psychosocial support intervention.
- Author
-
THALÉN-LINDSTRÖM, ANNIKA, LARSSON, GUNNEL, GLIMELIUS, BENGT, and JOHANSSON, BIRGITTA
- Subjects
ACADEMIC medical centers ,ANALYSIS of variance ,ANXIETY ,CANCER patients ,CHI-squared test ,MENTAL depression ,LONGITUDINAL method ,MEDICAL screening ,QUALITY of life ,RESEARCH funding ,T-test (Statistics) ,SOCIAL support ,DATA analysis software ,DESCRIPTIVE statistics - Abstract
Background. Anxiety and depression in cancer patients are associated with poor health-related quality of life (HRQOL). Clinical interventions to detect and support patients with these symptoms need to be developed and evaluated. We investigated the feasibility of screening with the Hospital Anxiety and Depression Scale (HADS) in a clinical oncology setting. In patients with anxiety or depression symptoms (HADS >7) we explored the use of clinical assessment and psychosocial support and described the development of anxiety, depression and HRQOL during a six-month period. Material and methods. Four hundred and ninety-five consecutive patients were screened for anxiety and depression at the time of their first visit at an oncology department (baseline). Half of the patients with HADS >7 on any of the two HADS subscales were referred to clinical assessment and psychosocial support (intervention group, IG) and half received standard care (SCG) using a historical control group design. HADS and EORTC QLQ-C30 were completed at baseline and after one, three and six months. Results. One hundred and seventy-six (36%) of 495 patients had anxiety or depression symptoms at screening, HRQOL at baseline was clearly impaired for them. Thirty-six (43%) of 84 IG patients attended clinical assessment, resulting in subsequent psychosocial support for 20 (24%) of them. In the SCG, only five (5%) patients attended clinical assessment after self referral, two received subsequent psychosocial support. Anxiety and depression decreased and HRQOL increased statistically significantly over time although anxiety was frequent and HRQOL impaired during the entire six month period. There were no differences between the SCG and IG regarding anxiety, depression or HRQOL at any time point. Conclusion. Systematic screening with HADS is feasible for oncology patients in clinical settings; it identifies patients with persistent symptoms and increases referral to clinical assessment and utilisation of psychosocial support. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
4. Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact.
- Author
-
NILSSON, CECILIA, JOHANSSON, IDA, AHLIN, CECILIA, THORSTENSON, STEN, AMINI, ROSE-MARIE, HOLMQVIST, MARLT, BERGKVIST, LEIF, HEDENFALK, INGRID, and FJÄLLSKOG, MARIE-LOUISE
- Subjects
BREAST cancer prognosis ,ACADEMIC medical centers ,BIOMARKERS ,IMMUNOHISTOCHEMISTRY ,MEDICAL records ,MOLECULAR diagnosis ,REGRESSION analysis ,EQUIPMENT & supplies ,PROPORTIONAL hazards models ,RETROSPECTIVE studies - Abstract
Background. Male breast cancer (MBC) is an uncommon disease and mere is limited information on the prognostic impact of routinely used clinicopathological parameters. Material and methods. In a retrospective setting, we reviewed 197 MBC patients with accessible paraffin-embedded tumor tissue and clinicopathological data. Immunohistochemical (IHC) stain-ings were performed on tissue microarrays and histological grading on conventional slides. Cox proportional regression models were applied for uni- and multivariate analyses using breast cancer death as the event. Results. Estrogen receptor (ER) and progesterone receptor positivity were demonstrated in 93% and 77% of patients, respectively. Nottingham histologic grade (NHG) III was seen in 41% and HER2 positivity in 11%. Classification into molecular subtypes using IHC markers according to three alternative definitions revealed luminal A and luminal B in 81% vs. 11%; 48% vs. 44% and 41% vs. 42% of cases. Two cases of basal-like were identified, but no cases of HER2-like. Factors associated with an increased risk of breast cancer death were node positivity (HR 4.5; 95% CI 1.8-11.1), tumor size >20 mm (HR 3.3; 95% CI 1.4-7.9) and ER negativity (HR 10.9; 95% CI 3.2-37.9). No difference in breast cancer death between the luminal subgroups was demonstrated, regardless of definition. Conclusion. MBC tumors were more often of high grade, whereas HER2 overexpression was as frequent as in FBC. Lymph nodes, tumor size and ER status were independent predictors of breast cancer death. The prognostic impact of molecular subtyping in MBC seems to differ from that previously established in FBC. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
5. Reference values for the EORTC QLQ-C30 quality of life questionnaire in a random sample of the Swedish population.
- Author
-
DEROGAR, MARYAM, VAN DER SCHAAF, MAARTJE, and LAGERGREN, PERNILLA
- Subjects
STATISTICAL correlation ,QUALITY of life ,QUESTIONNAIRES ,REFERENCE values ,RESEARCH funding ,DESCRIPTIVE statistics - Abstract
Aim. To obtain reference values for health-related quality of life (HRQL) measured with the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) in a random sample of the adult Swedish population. Methods. A population-based survey of a random sample of 7002 Swedish adults aged 40-79 years, frequency-matched to reflect the age and sex distribution of upper gastrointestinal cancer patients. Scales were scored on a 0-100 metric according to standard procedures. Functions and symptoms were dichotomized into "poor" versus "good" function, and "symptomatic" and "no or minor symptoms", respectively. The results were stratified for age and gender. Results. The questionnaire was completed by 4910 (70.5%) of 6969 eligible participants. Missing values were limited. HRQL was found to vary according to age and sex. Generally, men reported better functioning and fewer symptoms than women. The most common symptoms were fatigue, pain, and insomnia. Conclusion. The reference values provided can be used as a surrogate baseline measure in HRQL research, and when evaluating the effect of interventions on HRQL in cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
6. Costs and clinical outcome of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from gastric cancer.
- Author
-
HULTMAN, BO, LUNDKVIST, JONAS, GLIMELIUS, BENGT, NYGREN, PETER, and MAHTEME, HAILE
- Subjects
OPERATIVE surgery ,CANCER risk factors ,PERITONEAL cancer ,ACADEMIC medical centers ,COMBINED modality therapy ,CONFIDENCE intervals ,DRUG administration ,INTRAVENOUS therapy ,HEALTH outcome assessment ,PERITONEUM ,RESEARCH funding ,STOMACH tumors ,SURVIVAL ,COST analysis ,TREATMENT effectiveness ,DATA analysis software ,DESCRIPTIVE statistics ,KAPLAN-Meier estimator ,DISEASE complications - Abstract
Background. The costs for loco-regional treatment of peritoneal carcinomatosis from gastric cancer are not well investigated. The aims of this study were to evaluate the costs and clinical outcome of systemic chemotherapy followed by cytoreductive surgery and intraperitoneal chemotherapy compared to systemic chemotherapy only in patients with peritoneal carcinomatosis from gastric cancer. Material and methods. Ten patients were scheduled for systemic chemotherapy followed by loco-regional treatment. A reference group of 10 matched control patients treated with systemic chemotherapy only were used and both groups were evaluated with respect to clinical outcome and cost. Results. The mean overall cost in the loco-regional group was $145 700 (range 849 900-$487 800) and $59 300 (range $23 000-$94 800) for the control group. The mean overall survival for the loco-regional group was 17.4 months (range 6.0-34.3), and 11.1 months (range 0.1-24.2) for the systemic chemotherapy only group. The gain in life-years was 0.52 and in quality-adjusted life-years 0.49, leading to incremental cost per life-year and quality-adjusted life-years gained of $166 716 and $175 164, for loco-regional group compared to systemic chemotherapy. Discussion. Treatment of peritoneal carcinomatosis from gastric cancer is costly irrespective of treatment modality. If the survival benefit from adding loco-regional treatment to systemic chemotherapy indicated from this comparison is true, the incremental cost is considered high. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
7. Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity.
- Author
-
XUPING WU, HEDMAN, HÅKAN, BERGQVIST, MICHAEL, BERGSTRÖM, STEFAN, HENRIKSSON, ROGER, GULLBO, JOACHIM, LENNARTSSON, JOHAN, HESSELIUS, PATRIK, and EKMAN, SIMON
- Subjects
ANTINEOPLASTIC agents ,ACADEMIC medical centers ,BIOPSY ,EPIDERMAL growth factor ,ESOPHAGEAL tumors ,IMMUNOHISTOCHEMISTRY ,GENETIC mutation ,POLYMERASE chain reaction ,STATISTICS ,SURVIVAL ,DATA analysis ,REVERSE transcriptase polymerase chain reaction ,DESCRIPTIVE statistics ,KAPLAN-Meier estimator ,PROGNOSIS - Abstract
Background. Leucine-rich and immunoglobulin-like domains 1-3 (LRIG1-3) proteins have been implicated in the regulation of EGFR signalling. In the present study, we investigated the clinical implications of the expression of EGFR and LRIG 1-3 in oesophageal carcinoma, as well as the correlation between their expression levels and the chemosensitivity of oesophageal carcinoma cell lines. Patients and methods. Tumours from 80 patients with oesophageal carcinoma were investigated for the expression of EGFR and LRIG proteins by immunohistochemistry. Oesophageal carcinoma cell lines were investigated for their expression of EGFR and LRIG1, 2, and 3 by quantitative real time RT-PCR and for their sensitivity to commonly used chemotherapeutics by a cytotoxicity assay. Results and discussion: Based on a total score of intensity and expression rates, a trend towards survival difference was found for EGFR (p = 0.09) and LRIG2 (p = 0.18) whereas for LRIG1 and -3 there was no trend towards any association with survival. Correlation analysis revealed a correlation with the clinical expression of EGFR and LRIG3 (p = 0.0007). Significant correlations were found between LRIG1 expression levels and sensitivity to cisplatin (r = --0.74), docetaxel (r = --0.69), and vinorelbine (r = --0.82) in oesophageal carcinoma cell lines. EGFR and the LRIG proteins may be functionally involved in oesophageal carcinoma, but larger materials are needed to fully elucidate the clinical implication. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
8. Validation of oesophageal cancer surgery data in the Swedish Patient Registry.
- Author
-
LAGERGREN, KATARINA and DEROGAR, MARYAM
- Subjects
ACADEMIC medical centers ,CONFIDENCE intervals ,REPORTING of diseases ,ESOPHAGEAL tumors ,MEDICAL records ,RESEARCH evaluation ,OPERATIVE surgery ,BLIND experiment ,DESCRIPTIVE statistics - Abstract
Background. The Swedish Patient Registry provides data about diagnoses and surgical procedures for research purposes. There are, however, almost no validation studies of the data on surgical procedures, and none of oesophageal cancer surgery. Material and methods. This was a validation study of the accuracy of codes representing oesophageal cancer resection, surgical approach and oesophageal substitute in the Swedish Patient Registry during the period 1987-2005. The registered data were compared with a thorough review of the corresponding operation charts collected from medical records. Results. Among 1358 patients with a code representing oesophageal resection in the Patient Registry, the positive predictive value was 99.6%. The dominant surgical procedures in terms of surgical approach (transthoracic) and type of oesophageal substitute (gastric conduit) had positive predictive values of 99.8% and 99.4%, respectively. The more rare procedures with regards to approach (transhiatal) and substitute (bowel) had lower positive predictive values of 68.8% and 68.5%, respectively. Conclusion. The high accuracy of the data regarding oesophageal cancer resection in the Swedish Patient Registry stresses its appropriateness for research purposes. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
9. Predicting the survival of cancer patients recently diagnosed in Sweden and an evaluation of predictions published in 2004.
- Author
-
TALBÄCK, MATS and DICKMAN, PAUL W.
- Subjects
AGE distribution ,CANCER patients ,REPORTING of diseases ,PROGNOSIS ,SEX distribution ,SURVIVAL ,TUMORS ,DATA analysis software ,DESCRIPTIVE statistics - Abstract
Background. Estimates of cancer patient survival from traditional cohort-based methods may be heavily influenced by the survival experience of patients diagnosed many years ago and may not therefore be relevant to recently diagnosed patients. Period-based analysis provides better predictions of survival for recently diagnosed patients than cohort analysis. The first aim of this study is to provide predictions of the long-term survival of patients diagnosed in 2005-2009 using period analysis and to compare these estimates to the latest available cohort estimates. The second aim is to evaluate predictions published in 2004 regarding the future survival of patients diagnosed 2000-2002. Material and methods. We studied survival among patients diagnosed 1985-2009 reported to the nationwide, population-based Swedish Cancer Registry. Predictions of the future relative survival for recently diagnosed patients were made using period analysis with a window of 2005-2009. Results. The predictions made using period analysis and published in 2004 agreed well with the subsequently observed survival, with common sites showing a better agreement than less common sites. Updated predictions suggest that patients diagnosed today can expect improved survival for many forms of cancer. Conclusions. Period, rather than cohort, survival analysis should be used if the primary aim is to predict the future survival of recently diagnosed patients. Recently diagnosed cancer patients can, for many forms of cancer, expect an improved survival compared to patients diagnosed only a few years earlier. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
10. Curative radiation therapy in prostate cancer.
- Author
-
HARMENBERG, ULRIKA, HAMDY, FREDDIE C., WIDMARK, ANDERS, LENNERNÄS, BO, and NILSSON, STEN
- Subjects
TOMOGRAPHY ,ACADEMIC medical centers ,COMBINED modality therapy ,DOSE-response relationship in biochemistry ,PROSTATE tumors ,RADIATION doses ,RADIOTHERAPY ,STRATEGIC planning ,DATA analysis software - Abstract
Radiotherapy has experienced an extremely rapid development in recent years. Important improvements such as the introduction of multileaf collimators and computed tomography (CT)-based treatment planning software have enabled three dimensional conformal external beam radiation therapy (3DCRT). The development of treatment planning systems and technology for brachytherapy has been very rapid as well. Development of accelerators with integrated on-board imaging equipment and technology, for example image-guided radiation therapy (IGRT) has further improved the precision with reduced margins to adjacent normal tissues. This has, in turn, led to the possibility to administer even higher doses to the prostate than previously. Although radiotherapy and radical prostatectomy have been used for the last decades as curative treatment modalities, still there are no randomized trials published comparing these two options. Outcome data show that the two treatment modalities are highly comparable when used for low- and intermediate-risk prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
11. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
- Author
-
EINBEIGI, ZAKARIA, ENERBÄCK, CHARLOTTA, WALLGREN, ARNE, NORDLING, MARGARETA, and KARLSSON, PER
- Subjects
BRCA genes ,GENETIC mutation ,OVARIAN cancer ,BREAST cancer - Abstract
Aim: In a previous cohort study, we showed that there was a significant variation in the frequency of ovarian cancer after having breast cancer in Sweden, with the highest risk occuring in the Western region. The present study aimed to evaluate whether the high prevalence of the founder mutation BRCA1 3171ins5 may explain the excess number of ovarian cancer. Method: Among more than 26 000 women with breast cancer in the Western Swedish Health Care Region, 159 cases were subsequently diagnosed with ovarian cancer, whereas the expected number was 96. Archived tissue material was analysed for six common Scandinavian BRCA1 and BRCA2 gene mutations. Results: The excess number of cases was 63 (95% CI 47-77), based on person-years at risk and national incidence rates of ovarian cancer. A BRCA1 gene mutation was detected in 33 cases corresponding to 52% of the excess number. The founder mutation, BRCA1 3171ins5, was detected in 44% of the excess number. The identified mutations decreased from 45% in women less than 50 years of age at follow-up to 14% at 60+ years at follow-up. There was no obvious decrease in mutation frequency by excess numbers with age. Age at follow-up and first-degree relatives with breast and/or ovarian cancer were the best predictors of a mutation in this material. Conclusion: The founder mutation, BRCA1 3171ins5, explains the excess of ovarian cancer after breast cancer in the region. From the relative frequency of the studied mutations found at the cancer genetic counselling clinic, it is estimated that BRCA1 gene mutations are associated with about 80-85% of the excess cases. This means that a negative screening for these mutations in similar cases may have a predictive value and could strongly reduce the risk of ovarian cancer in relatives. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.